This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 results approved; quarterly revenue and profit not in text
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.5 pts less than Nifty Microcap 250 and 5.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
For the consolidated quarter ended 30 September 2026, the provided text gives no revenue or profit after tax, so comparison with 30 September 2025 cannot be confirmed. For the half year ended 30 September 2026, consolidated profit before tax rose about 91% to Rs 4,000.74 million from Rs 2,099.32 million; operating cash flow was Rs 3,215.16 million. Board-approved results received an unmodified review; the group acquired QliniQ B.V. and ABCnow GmbH.
Strong half-year profit and cash generation are positive, but missing quarterly revenue and profit figures limit assessment of share-price impact.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹940.2 Cr | ₹720.4 Cr | +30.5% |
| Operating profit | ₹175.4 Cr | ₹111.8 Cr | +56.9% |
| Profit after tax | ₹143.5 Cr | ₹99.14 Cr | +44.8% |
| EBITDA margin | 22.8% | 20.1% | +2.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.